* If you want to update the article please login/register
There is a lot of similarity between adult growth hormone deficiency and those of Gulf War Illness, including exhaustion, chronic pain, depression, and cognitive dysfunction. According to studies, GHRT causes chronic pain, mood disruption, cognitive function, and quality of life in civilians with AGHD attributed to other conditions such as brain tumors. This is phase II, controlled, double-blind, placebo-controlled futility research examining the efficacy and safety of GHRT as a treatment option for patients with a history of AGHD and GWI. The primary outcome is to determine truncal fat mass percentage determined by dual energy x-ray absorptiometry, to determine the efficacy of GHRT versus placebo.
Source link: https://clinicaltrials.gov/ct2/show/NCT05355272
This report is aimed at women in menopause who have moderate to severe hot flashes. A placebo is a dummy treatment that looks like fezolinet but does not have any medicine in it, as shown by this analysis. The aim of the study will determine whether fezolinetant reduces the number and severity of hot flashes by comparing fezolinetant with placebo. Women who want to enroll in the study will be given an electronic handheld device with an app to monitor their hot flashes. Some women may be able to use the app on their own smartphone. The women will record their hot flashes in the last ten days before their next clinic visit. For 24 weeks, women who enroll in the study will take two tablets every day for 24 weeks. That means that the women in the study and the research doctors will not know who takes which of the study medications if they know who has which of the study's will not know who prescribes which of the study's drugs is which. The women will continue to post updates about their hot flashes on their electronic device or phone. The women will return to their academic clinic several times for a check-up during the study. From Week 2 to Week 20, some women may be able to have home visits instead. The women will have an ECG to check their heart rhythm in Week 2 and Week 24. A transvaginal ultrasound will also be performed for women with a uterus. A photograph of the organs in the pelvis can be obtained by sound waves.
Source link: https://clinicaltrials.gov/ct2/show/NCT05033886
The in utero period has been shown to be a period of relative fetal sensitivity to immune stimuli, and this tolerance may lead to improved response to ERT in situations where postnatal initiation causes antibody formation and delayed response to therapy. It is also likely that in some cases, initiation of ERT in utero leads to improved neurodevelopmental outcomes, if the replaced enzyme affects the neurologic system during critical periods of development. This is a phase 1 clinical trial to find the safety and effectiveness of fetal enzyme replacement therapy in fetuses with LSD.
Source link: https://clinicaltrials.gov/ct2/show/NCT04532047
Cigarette smoking is a contributing factor in coronary heart disease formation, and it is the most harmful form of tobacco use. Effective smoking cessation products do exist, but relapse to cigarette smoking is common, mainly due to nicotine dependence and withdrawal symptoms. Cytisine acts by reducing the rewarding effect of nicotine withdrawal and attenuating nicotine withdrawal symptoms. According to a recent report, cytisine is the most effective future smoking cessation treatment. At one week and 1, 2 and 6 months when both groups received no behavioural assistance, one high-quality pragmatic non-inferiority trial concluded that cytisine was superior to nicotine replacement therapy in raising self-reported continuous abstinence rates at 1 week and 1, 2, and 6 months. Following hospitalization for a CHD-related disease, the long-term aim is to conduct a scientific, large-scale controlled trial of cytisine's effectiveness relative to conventional therapy for smoking cessation among smokers who have relapsed to smoking following hospitalization for a CHD-related disease.
Source link: https://clinicaltrials.gov/ct2/show/NCT04286295
Testosterone has an effect on multiple body functions, including muscle mass and quality. Mr Jenkins and his staff are now looking at ways to prevent or reduce muscle loss in order to improve patient outcomes. Patients who are suffering from colorectal cancer and are awaiting to have surgery are able to determine whether using testosterone replacement therapy in the form of a topically applied gel daily for a total of 12 weeks is safe and acceptable by the patients who are diagnosed with colorectal cancer and are waiting for surgery.
Source link: https://clinicaltrials.gov/ct2/show/NCT05367284
Patients who underwent complete thyroidectomy or complete thyroidectomy and require levothyroxine replacement therapy will be included in this study. According to the Poisson regression model algorithm, patients in the other group would be doingsing LT4 for patients. Wen't even say which patients will experience euthyroidism in a more effective manner.
Source link: https://clinicaltrials.gov/ct2/show/NCT05240911
Onasemnogene abeparvovec-xioi in patients with spinal muscular atrophy Type 1 who meet enrollment requirements and are genetically determined by a biallelic pathogenetic mutation of the survival motor neuron 2 gene in one or two copies of the survival motor neuron 2 gene varies by a biallelic pathogenetic mutation of the survival motor neuron 2 gene. Patients who meet the entry requirements will be eligible for the in-patient gene replacement therapy period. Patients will return to regular scheduled intervals for efficacy and safety testing until the patient reaches the age of 18 months of age during the outpatient sequel to Outpatients. Patients eligible patients will be invited to participate in the long-term follow-up trial following the conclusion of the end of the trial. All post-treatment visits will be related to the date on which gene replacement therapy is started up until the patient is 14 months of age, after which they will be relevant to the patient's date of birth.
Source link: https://clinicaltrials.gov/ct2/show/NCT03461289
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions